1. Home
  2. ARGX vs EA Comparison

ARGX vs EA Comparison

Compare ARGX & EA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARGX
  • EA
  • Stock Information
  • Founded
  • ARGX 2008
  • EA 1982
  • Country
  • ARGX Netherlands
  • EA United States
  • Employees
  • ARGX N/A
  • EA N/A
  • Industry
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • EA Computer Software: Prepackaged Software
  • Sector
  • ARGX Health Care
  • EA Technology
  • Exchange
  • ARGX Nasdaq
  • EA Nasdaq
  • Market Cap
  • ARGX 33.0B
  • EA 37.9B
  • IPO Year
  • ARGX 2017
  • EA N/A
  • Fundamental
  • Price
  • ARGX $543.48
  • EA $155.37
  • Analyst Decision
  • ARGX Strong Buy
  • EA Buy
  • Analyst Count
  • ARGX 17
  • EA 21
  • Target Price
  • ARGX $730.07
  • EA $165.30
  • AVG Volume (30 Days)
  • ARGX 399.5K
  • EA 2.8M
  • Earning Date
  • ARGX 07-24-2025
  • EA 07-29-2025
  • Dividend Yield
  • ARGX N/A
  • EA 0.49%
  • EPS Growth
  • ARGX N/A
  • EA N/A
  • EPS
  • ARGX 15.94
  • EA 4.25
  • Revenue
  • ARGX $2,643,062,000.00
  • EA $7,463,000,000.00
  • Revenue This Year
  • ARGX $61.64
  • EA $8.08
  • Revenue Next Year
  • ARGX $32.00
  • EA $5.59
  • P/E Ratio
  • ARGX $31.65
  • EA $36.56
  • Revenue Growth
  • ARGX 82.13
  • EA N/A
  • 52 Week Low
  • ARGX $432.96
  • EA $115.21
  • 52 Week High
  • ARGX $678.21
  • EA $168.50
  • Technical
  • Relative Strength Index (RSI)
  • ARGX 40.56
  • EA 57.62
  • Support Level
  • ARGX $510.06
  • EA $156.86
  • Resistance Level
  • ARGX $563.36
  • EA $160.99
  • Average True Range (ATR)
  • ARGX 15.01
  • EA 2.49
  • MACD
  • ARGX -0.68
  • EA 0.36
  • Stochastic Oscillator
  • ARGX 45.72
  • EA 59.89

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

About EA Electronic Arts Inc.

Electronic Arts is one of the largest global developers and publishers of video games. Its most important franchises are the Madden NFL and FC soccer games, which it releases annually. In 2024, it also relaunched its American college football game. Other major franchises include Apex Legends, Battlefield, and The Sims. Typically, about three quarters of the firm's sales are from in-game spending, with the remainder coming from initial game sales.

Share on Social Networks: